Research progress of hepatitis C in 2018 / 中华肝脏病杂志
Chinese Journal of Hepatology
; (12): 6-9, 2019.
Article
em Zh
| WPRIM
| ID: wpr-810364
Biblioteca responsável:
WPRO
ABSTRACT
Up to now, all major direct-acting antiviral agents (DAAs) have been approved, pan-genotypic regimens are recommended globally, simple monitoring strategy is recommended. In 2018, hepatitis C research focused more on accessibility, rather than new regimens. With the joint efforts of government and social groups, more infected people are getting affordable treatment. In addition approval of DAAs from global pharmaceuticals, a variety of DAAs have been on the clinical trial and approved in our country, and more options are/will be available with clinical trials progress. Management of infected fetus, children, and pregnant women will attract researchers’ attention.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Chinese Journal of Hepatology
Ano de publicação:
2019
Tipo de documento:
Article